Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: A systematic review and meta-analysis

Abstract

Background:

Several studies have been conducted to evaluate the prognostic value of prothrombin induced by vitamin K absence-II (PIVKA-II) overexpression in hepatocellular carcinoma patients treated with curative ablation. However, the results remain controversial. The purpose of this meta-analysis was to explore the correlation between PIVKA-II expression and survival outcomes in these patients.

Methods:

We performed a systematic literature search in PubMed, EMBASE, Medline, Cochrane Library, and Web of Science to identify the relevant articles investigating the prognostic value of PIVKA-II in patients with hepatocellular carcinoma. Combined hazard ratios (HR) and their 95% confidence intervals (CI) for overall survival and recurrence-free survival were calculated as the analysis endpoints.

Results:

A total of 15 cohorts encompassing 5647 patients were included. The results indicated that elevated PIVKA-II was significantly associated with poorer overall survival (HR 1.59; 95% CI 1.40, 1.82; P < 0.001) and recurrence-free survival (HR 1.76; 95% CI 1.42, 2.17; P < 0.001). Similar results were observed in the subgroup analysis based on sample size, analytical method, treatment modality, and cut-off value.

Conclusions:

This meta-analysis suggests that elevated PIVKA-II is a predictor of unfavorable overall survival and recurrence-free survival in hepatocellular carcinoma patients receiving curative ablation. More rigorous studies are warranted to confirm the clinical utility of PIVKA-II in determining hepatocellular carcinoma prognosis.

Keywords

Hepatocellular carcinoma ablation PIVKA-II prognosis meta-analysis

Introduction

Hepatocellular carcinoma (HCC) is one of the most predominant and aggressive malignancies in the world. This type of carcinoma is the fifth most common cause of cancer-related death in males and the eighth in females.¹ During the last few decades, periodic surveillance in high-risk people has not only enabled the diagnosis of HCC at an early stage but also promoted the application of curative treatments, such as hepatic resection and percutaneous ablation.² Although hepatic resection is usually the first treatment option to consider, the application is still limited in the majority of patients owing to impaired liver function.³ Recently, percutaneous ablation, including thermal ablation and percutaneous ethanol injection, has gained increasing popularity as a safe, less invasive, and easily repeated treatment modality in small HCC. These ablative therapies can be utilized in patients who are ineligible for hepatic resection and have shown favorable survival rates with excellent curability.⁴

Despite the rapid progression in treatment modalities and early diagnostic techniques, the long-term outcome of HCC after ablation remains disappointing. Although serum alpha-fetoprotein (AFP) has been considered an important surveillance marker of HCC for several decades, its prognostic capability is not satisfactory.⁴ It can be elevated in patients with chronic hepatitis or liver cirrhosis in the absence of cancer.⁵ The expression of AFP is also found to have no prognostic effect in patients with single, small HCC receiving curative therapy.⁶ Hence, the investigation of more efficient predictive makers for HCC is of great clinical importance.

Prothrombin, containing 10 γ-carboxyglutamic acid (Gla) residues in the amino-terminal domain, is synthesized in the liver.⁷ Prothrombin is a vitamin K-dependent plasma coagulation factor. Vitamin K deficiency or ingestion of vitamin K antagonists can inhibit the activity of vitamin K-dependent carboxylase, leading to an acquired defect of post-translational carboxylation of the glutamic acid (Glu) residues on the prothrombin precursor. As a result, abnormal prothrombin (PIVKA-II), without γ-carboxylation of all its Glu residues, is released into the plasma. The correlation between PIVKA-II levels and HCC was first reported by Liebman et al.⁸ in 1984. Since then, accumulating evidence has revealed that PIVKA-II may be a useful diagnostic and prognostic tumor marker for HCC.^9-12

Unfortunately, the prognostic value of PIVKA-II in HCC patients treated with ablation is controversial and has not yet been methodically analyzed. Some studies concluded that high expression of PIVKA-II was associated with worse prognosis in patients with HCC,^13-16 while others did not show any significant correlation between PIVKA-II and clinical outcomes.^17-20 We therefore performed this meta-analysis to elucidate the prognostic value of increased PIVKA-II on overall survival (OS) and recurrence-free survival (RFS) in HCC patients receiving curative ablation by pooling outcomes from obtainable data.

Materials and methods

This systematic review and meta-analysis was performed strictly in accordance with PRISMA guidelines. Before the initiation of the review process, we registered a review protocol at PROSPERO.org with registration number CRD42017063996.

Search strategy

A comprehensive search of PubMed, EMBASE, Medline, Cochrane Library, and Web of Science databases was performed in March 2017 using the following terms: “hepatocellular carcinoma” or “liver cancer” or “hepatoma” or “HCC”; and “prognosis” or “prognostic” or “survival” or “recurrence”; and “decarboxyprothrombin” or “des-gamma-carboxy prothrombin” or “des-γ-carboxy prothrombin” or “DCP” or “PIVKA-II”; and ablation. The citations reported in selected studies were then carefully screened to seek potential eligible publications.

Inclusion and exclusion criteria

The included studies fulfilled the following criteria: (a) the study evaluated the prognostic role of PIVKA-II in HCC patients undergoing percutaneous ablation therapy; (b) PIVKA-II was detected using serum-based methods before treatment; (c) the study provided sufficient data of hazard ratios (HRs) and 95% confidence intervals (CIs) for OS and RFS; and (d) the study was published as a full paper in English. When multiple studies reported by the same institution or authors were identified, the most recent or most complete study was chosen. Conference records, case reports, reviews, letters, and non-English language studies were excluded. Two reviewers (Zhang and Liu) selected the studies in duplicate according to the criteria mentioned above. Inconsistencies were resolved by discussion or re-evaluation with the third author.

Data extraction and quality assessment

Data were extracted by two investigators independently. The details of each article were recorded as follows: first name of the author, publication year, sample size, median/mean age, cut-off value, PIVKA-II overexpression, outcome measures, analytical method, treatment modality, HR, and associated 95% CI. When the study provided both multivariable and univariate analysis for HR, only the result of multivariable analysis was selected.

The Newcastle-Ottawa Scale (NOS) is a quality assessment scale that was adopted to evaluate the quality of all primary studies. The scale consists of eight questions that focus on the assessment of cohort selection, study comparability, and outcome assessment. NOS scores ranged from zero to nine, and studies with scores above six were considered to have a high methodological quality.

Statistical analysis

Stata Version 14.0 (StataCorp, College Station, TX, USA) was utilized to carry out the statistical analyses. HRs with corresponding 95% CIs were aggregated to measure the prognostic significance of PIVKA-II in HCC patients. In the case that a study did not provide exploitable information, the statistics were extracted indirectly from available numerical data or Kaplan–Meier curves according to the methods suggested by Tierney et al.²¹ A pooled HR value greater than one was indicative of a worse outcome for patients with high PIVKA-II levels. The heterogeneity across studies was evaluated by Higgins I² statistic and Cochran’s Q test. A P value < 0.05 and/or I² > 50% denoted studies of substantial heterogeneity. In that case, the random-effect model was employed to assess the pooled HRs; otherwise, the fixed-effect model was applied. Publication bias was evaluated using the funnel plot and Egger’s test. In order to estimate the reliability of the prognostic outcomes, we also performed the sensitivity analysis. All statistical tests with P < 0.05 were considered to indicate statistically significant.

Results

Study characteristics

The selection process of the included studies is shown in Figure 1. A total of 202 records were identified through the literature search. Among these records, 98 duplicate articles were removed. We then excluded 73 articles by scanning the title and abstract. Ultimately, 14 eligible studies (15 cohorts) containing 5674 participants were included in the data analyses after a full-text review. The study by Minami et al.²² evaluated the prognostic role in two different cohorts and reported the HR and 95% CI separately.

Figure 1.

Flowchart of the study selection process.

The major characteristics of each study are presented in Table 1. The quality of the eligible studies was assessed by NOS scores, which ranged from six to eight for these studies. All eligible cohorts were conducted in Asian countries, including 14^13-20,22-26 in Japan and one²⁷ in Korea. The sample size varied from 99 to 1219, and the mean (median) age of the study patients varied from 57 to 73 years old. Of the 15 cohorts, nine^{13,15,16,18-20,25-27} reported radiofrequency ablation (RFA) as the therapeutic intervention for HCC, whereas patients in the remaining six cohorts^14,17,22-24 were treated with local ablation therapy (LAT), including percutaneous microwave coagulation therapy, percutaneous ethanol injection, and radiofrequency ablation. Nine cohorts^{13-17,22,26,27} focused on the prognostic role of PIVKA-II for OS, and 11^{14-16,18-20,23-27} for RFS. All the enrolled patients in two cohorts had hepatitis B virus (HBV)-related hepatocellular carcinoma. Among the 15 involved cohorts, 14 of them were retrospective in design, with only one²⁴ based on a prospective cohort. The cut-off values were determined by the investigators and were different in these studies.

Table 1.

Baseline characteristics of the included studies.

Study	Year	Sample size	Mean/median age (years)	Cut-off value	Overexpression n (%)	Outcome measures	Multivariate analysis	Treatment modality	NOS score
Tateishi et al.²³	2006	419	67	100	68 (16.4)	RFS	yes	LAT	8
Morimoto et al.¹⁷	2007	153	69	300	20 (13)	OS	yes	LAT	7
Takahashi et al.¹³	2008	171	69	100	NR	OS	yes	RFA	7
Toyoda et al.¹⁴	2008	456	68	100	108 (23.7)	OS/RFS	yes/no	LAT	6
Kobayashi et al.¹⁵	2009	209	67	100	13 (7.0)	OS/RFS	yes	RFA	7
Beppu et al.¹⁸	2010	108	67	40	44 (41)	RFS	yes	RFA	7
Tamura et al.²⁴	2010	99	69	40	72 (32.6)	RFS	yes	RFA	7
Nishikawa et al.¹⁹	2011	269	69	200	42 (15.6)	RFS	yes	RFA	6
Shiina et al.¹⁶	2012	1170	68	400	196 (16.9)	OS/RFS	yes	RFA	6
Minami et al.²²	2015a	166	60	100	35 (22)	OS	yes	LAT	7
Minami et al.²²	2015b	1219	68	100	156 (13)	OS	yes	LAT	7
Dohi et al.²⁵	2016	357	73	40	NR	RFS	yes	RFA	6
Lee et al.²⁷	2016	412	57	40	92 (22.3)	OS/RFS	no	RFA	6
Tajiri et al.²⁶	2016	163	72	40	NR	OS/RFS	no/yes	RFA	6
Kawamura et al.²⁰	2017	303	70	100	NR	RFS	yes	RFA	6

LAT: local ablation therapy; NOS: Newcastle-Ottawa Scale, for quality assessment; NR: not reported; OS: overall survival; RFA: radiofrequency ablation; RFS: recurrence-free survival.

PIVKA-II and OS in HCC

Nine cohorts involving 4149 patients provided sufficient data for OS analysis. As shown in Figure 2, the fixed-effect model was utilized to verify the relationship between PIVKA-II and OS. The combined data demonstrated that elevated PIVKA-II obviously correlated with a worse OS (HR 1.59; 95% CI 1.40, 1.82; P < 0.001; I² = 47.9%, P = 0.052) when compared to a low PIVKA-II.

Figure 2.

Forest plot of studies evaluating the association between high PIVKA-II levels and OS in HCC patients.

Subgroup analysis was conducted to further investigate the potential source responsible for the heterogeneity. As shown in Table 2, a significant relationship between high PIVKA-II and poor OS was detected in HCC both when sample size < 400 (HR 2.39; 95% CI 1.74, 3.29) and sample size ≧ 400 (HR 1.47; 95% CI 1.28, 1.70). In terms of treatment modality, the results indicated that PIVKA-II was an unfavorable predictor of prognostic in HCC patients initially treated by RFA with an HR of 1.59 (95% CI 1.40, 1.82) and LAT with an HR of 1.45 (95% CI 1.25, 1.69). Similar results were observed in the stratified analysis by cut-off value and treatment modality. The summary HRs for OS were significantly different when grouped according to the sample size (P_D = 0.007) and treatment modality (P_D = 0.016). In contrast, differences across subgroups of analytical method (P_D = 0.151) and cut-off value (P_D = 0.277) were not statistically significant.

Table 2.

Summary of the subgroup analyses.

Analysis	No. of studies	Pooled hazard ratio (95% CI)	P value	P_D value	Heterogeneity
Analysis	No. of studies	Pooled hazard ratio (95% CI)	P value	P_D value	I² (%)	P _h
OS	9	1.59 (1.40, 1.82)	<0.001		47.9	0.052
Sample size				0.007
≧400	4	1.47 (1.28, 1.70)	<0.001		0	0.393
< 400	5	2.39 (1.74, 3.29)	<0.001		20.5	0.284
Analytical method				0.151
Multivariate	6	1.53 (1.33, 1.76)	<0.001		62.0	0.022
Univariate	3	2.01 (1.43, 2.82)	<0.001		0	0.937
Treatment modality				0.016
RFA only	5	1.59 (1.40, 1.82)	<0.001		43.6	0.131
LAT	4	1.45 (1.25, 1.69)	<0.001		0	0.487
Cut-off value				0.277
≧100	7	1.56 (1.36, 1.79)	<0.001		57.3	0.029
= 40	2	2.01 (1.30, 3.10)	0.002		0	0.719
RFS	11	1.76 (1.42, 2.17)	<0.001		66.6	0.001
Sample size				0.022
≧400	4	1.42 (1.24, 1.63)	<0.001		48.8	0.119
<400	7	1.87 (1.55, 2.26)	<0.001		68.1	0.004
Analytical method				0.022
Multivariate	9	1.95 (1.50, 2.54)	<0.001		63.6	0.005
Univariate	2	1.31 (1.11, 1.55)	0.001		0	0.684
Treatment modality				0.022
RFA only	8	1.75 (1.51, 2.02)	<0.001		66.9	0.004
LAT	3	1.35 (1.14, 1.59)	0.012		43.7	0.170
Cut-off value				0.359
≧100	6	1.55 (1.35, 1.78)	<0.001		81.2	<0.001
=40	5	1.58 (1.32, 1.88)	<0.001		0	0.499

CI, confidence interval; LAT: local ablation therapy; OS, overall survival; P_D: P for subgroup difference; RFA: radiofrequency ablation; RFS: recurrence-free survival.

PIVKA-II and RFS in HCC

Eleven cohorts were included to investigate the relationship between PIVKA-II and RFS in patients with HCC. Considering the significant heterogeneity (I² = 66.6%; P = 0.001; Figure 3) between studies, we employed the random-effect model to pool the HR. Pooled data showed that patients with high PIVKA-II exhibited shortened RFS with a combined HR of 1.76 (95% CI 1.42, 2.17; P < 0.001). Subgroup analysis based on the number of patients indicated that studies with large sample size (HR 1.42; 95% CI 1.24, 1.63; P < 0.001) were correlated with a smaller effect when compared with small sample size (HR 1.87; 95% CI 1.55, 2.26; P < 0.001). In the analysis according to the analytical method, studies assessed by univariate analysis (HR 1.31; 95% CI 1.11, 1.55; P = 0.001) and multivariate analysis (HR 1.95; 95% CI 1.50, 2.54; P < 0.001) gave identical results. Significant HR was found in both RFA group (HR 1.75; 95% CI 1.51, 2.02; P < 0.001) and LAT group (HR 1.35; 95% CI 1.14-1.59; P = 0.012). Similarly, the results did not change in the subgroup analysis of cut-off value (≧100: HR 1.55; 95% CI 1.35, 1.78; P < 0.001; and = 40: HR 1.58; 95% CI 1.32, 1.88; P < 0.001).

Figure 3.

Forest plot of studies evaluating the association between high PIVKA-II levels and RFS in HCC patients.

Sensitivity analysis

Sensitivity analysis showed that the combined outcomes were not materially changed by eliminating any single study, indicating the robustness of our meta-analysis (Supplementary Figure1). It is important to note that the heterogeneity between the remaining studies was strikingly decreased when the study by Kobayashi et al.¹⁵ was omitted (I² = 12.2%; P = 0.335 for OS; and I² = 13.1%; P = 0.323 for RFS), which meant this study might contribute to the heterogeneity in both OS and RFS analyses. Removing this over-weighted study, the elevated PIVKA-II levels still had a significant impact on the prognostic outcomes (HR 1.55; 95% CI 1.36, 1.77 for OS; and HR 1.50; 95% CI 1.34, 1.67 for RFS).

Publication bias

Visual inspection of the funnel plots exhibited asymmetry for both OS and RFS. Consistently, the P value of Egger’s test also implied the presence of publication bias among the included studies (P = 0.005 in OS and P=0.026 in RFS). We therefore conducted a trim-and-fill analysis to adjust the publication bias. The results indicated that the pooled analysis incorporating the unpublished studies did not alter the significant prognostic impact of elevated PIVKA-II, and the adjusted HR would be 1.46 (95% CI 1.30,1.65; P<0.001) for OS and 1.44 (95% CI 1.14, 1.83; P=0.003) for RFS.

Discussion

Recent advances in therapeutic interventions and imaging techniques have dramatically improved the survival outcomes of HCC patients. RFA, which has yielded comparable survival outcomes compared with surgical resection, is recommended in most instances as the main ablative therapy. Additionally, RFA was suggested to be the most cost-effective therapeutic strategy for early HCC.²⁸ However, recurrence and distant metastasis after ablation are still frequently encountered, which highlights the need for exploring a more efficient prognostic biomarker for patients with HCC.

PIVKA-II, also known as des-gamma-carboxy prothrombin (DCP), is an abnormal prothrombin lacking coagulant activities. PIVKA-II is a well-recognized biomarker in the diagnosis of HCC, and it has been suggested as a prognostic indicator for survival and recurrence after curative treatment.^29,30 Nevertheless, the exact role of elevated PIVKA-II in HCC patients receiving percutaneous ablation remains obscure.

To the best of our knowledge, the present meta-analysis is the first one to comprehensively explore the prognostic significance of elevated PIVKA-II in HCC patients. In this meta-analysis, we included 15 cohorts encompassing 5647 patients to evaluate the usefulness of PIVKA-II in predicting the survival outcomes for HCC patients after curative ablation. It was demonstrated that the excessive production of PIVKA-II was significantly correlated with shortened OS and RFS in HCC patients. We also investigated the influence of sample size, analytical method, treatment modality, and cut-off value on the pooled outcomes by subgroup analysis. As a result, no substantial alteration was observed, suggesting that PIVKA-II is a promising predictive marker to assist clinicians in making optimal decisions regarding treatment and outcomes. Adjuvant chemotherapy and careful follow-up after curative ablation should be necessary for patients with a high PIVKA-II level.

Statistical heterogeneity was detected in this meta-analysis. It is most likely due to the study by Kobayashi et al.¹⁵ in which the high levels of PIVKA-II played a more superior prognostic role in HCC patients. The sensitivity analysis showed that after removing this outlier study, the heterogeneity in the remaining publications was strikingly decreased. The most plausible explanation for this could be related to the sample size. As we all know, studies with a smaller sample size are more prone to obtain a higher effect value. It was found that the number of patients with elevated PIVKA-II in the Kobayashi et al.¹⁵ study was much smaller compared with those in the other studies, which may lead to an overestimation of the prognostic value of PIVKA-II. Furthermore, the conclusion of our meta-analysis was not altered after the sensitivity analysis, which further confirmed the reliability of the results.

Many researchers noted that PIVKA-II appeared to be a better diagnostic marker in comparison with AFP for HCC patients.^7,9,29,31 This finding is compatible with the results of a meta-analysis conducted by Li et al.³² That meta-analysis included 49 studies and demonstrated that PIVKA-II showed more diagnostic accuracy than AFP, especially in diagnosing early-stage HCC. In our meta-analysis, we also attempted to compare the prognostic value of PIVKA-II with AFP in HCC patients treated with curative ablation. Among the 15 included cohorts, eight provided sufficient information to investigate the predictive ability of AFP, which indicated that pretreatment AFP values may have a worse prognostic effect than PIVKA-II in HCC patients. In addition, five of the included cohorts suggested that no difference was found in clinical outcomes between patients with and without elevated serum AFP, but they only offered the relevant P values. More effort should be made to validate whether PIVKA-II has more superior diagnostic and prognostic effect than AFP in HCC patients.

It is important to note that PIVKA-II does not always directly reflect the development of HCC. Serum PIVKA-II levels can be aberrantly elevated in patients with prolonged obstructive jaundice, vitamin K deficiency, or those taking vitamin K antagonists (e.g. warfarin) even in the absence of HCC. Hence, the prognostic value of PIVKA-II would be significantly diminished in these subpopulations. In order to improve the clinical utility of PIVKA-II, a novel PIVKA-II assay (NX-PVKA) measured by P-11 and P-16 antibodies has been developed.³³ It was reported that NX-PVKA could identify the elevation of PIVKA-II owing to HCC in patients taking anticoagulants.³⁴ Further studies are necessary to clarify the prognostic effect of NX-PVKA.

Although our meta-analysis revealed that the overexpression of PIVKA-II was an efficient prognostic marker for HCC, the exact mechanism of its correlation with survival outcomes has not been well understood. PIVKA-II is a novel type of vascular endothelial growth factor (VEGF) possessing potent mitogenic and migrative activities.³⁵ As reported in previous studies, PIVKA-II was identified to stimulate the proliferation of HCC cells through activating the Met-JAK1-STAT3 signaling pathway.³⁶ Fujikawa et al.³⁷ found that PIVKA-II induced both DNA synthesis and cell migration in human umbilical vein endothelial cells, and the biological effect was brought out by directly binding to the kinase insert domain receptor. Moreover, several studies showed that PIVKA-II significantly stimulated the expression of angiogenic factors in HCC cells, such as VEGF, epidermal growth factor receptor, and matrix metalloproteinase.^38,39

Several limitations should be acknowledged in the present meta-analysis. First, most of the included studies were based on retrospective cohorts, and subject selection bias is unavoidable in these articles. Second, all the eligible studies were conducted in Asia, in which the demography and liver disease etiology for HCC are substantially different from those in Western societies. It is worth noting that in a study conducted in France, the investigators suggested that PIVKA-II could be used for prognostic assessment because increased PIVKA-II was strongly correlated with the presence of microvascular invasion.¹² However, more studies should be performed to shed light on the prognostic role of PIVKA-II in various geographic populations. Third, the association between elevated PIVKA-II and the clinicopathological parameters was not estimated, and the impact of these factors on the prognostic value of PIVKA-II failed to be illuminated due to the limited data. Furthermore, the cut-off values used in the included studies were not unified, which might influence the reliability of our results. Despite this, the prognostic significance of PIVKA-II was not affected by different cut-off values according to the subgroup analysis. Finally, the publication bias was a concern, although we tried to recognize all relevant data. Nonetheless, the trim-and-fill analysis showed that the pooled effect size was still significant even if the negative results were published.

In conclusion, it is indicated that the overexpression of PIVKA-II in pretreatment samples is correlated with a poor prognosis in HCC patients that receive curative ablation. This finding may be helpful in determining optimal treatment therapeutics for HCC patients. Considering the limitation of our analysis, further well-designed, large-scale, and multicenter prospective studies are warranted to validate the prognostic power of PIVKA-II.

Supplemental Material

Supplementary – Supplemental material for Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: A systematic review and meta-analysis

Supplemental material, Supplementary for Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: A systematic review and meta-analysis by Dongjing Zhang, Zhihong Liu, Xueru Yin, Xiaolong Qi, Bingyun Lu, Yuanyuan Liu and Jinlin Hou in The International Journal of Biological Markers

Footnotes

Declaration of conflicting interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

Siegel

Miller

Jemal

Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.

de Lope

Tremosini

Forner

et al . Management of HCC. J Hepatol 2012; 56: S75–S87.

Tiong

Maddern

GJ.

Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg 2011; 98: 1210–1224.

Lencioni

Crocetti

Local-regional treatment of hepatocellular carcinoma. Radiology 2012; 262: 43–58.

Di Bisceglie

Sterling

Chung

et al . Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005; 43: 434–441.

Giannini

Marenco

Borgonovo

et al . Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology 2012; 56: 1371–1379.

Masuzaki

Karp

Omata

New serum markers of hepatocellular carcinoma. Semin Oncol 2012; 39: 434–439.

Liebman

Furie

Tong

et al . Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310: 1427–1431.

Marrero

Wei

et al . Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003; 37: 1114–1121.

10.

Hakamada

Kimura

Miura

et al . Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1370–1377.

11.

Inagaki

Tang

Makuuchi

et al . Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-gamma-carboxyprothrombin. Liver Int 2011; 31: 22–35.

12.

Pote

Cauchy

Albuquerque

et al . Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol 2015; 62: 848–854.

13.

Takahashi

Kudo

Chung

et al . PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy. Oncology 2008; 75: 91–98.

14.

Toyoda

Kumada

Kaneoka

et al . Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol 2008; 49: 223–232.

15.

Kobayashi

Ikeda

Kawamura

et al . High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009; 115: 571–580.

16.

Shiina

Tateishi

Arano

et al . Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012; 107: 569–578.

17.

Morimoto

Numata

Sugimori

et al . Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. World J Gastroenterol 2007; 13: 1003–1009.

18.

Beppu

Sugimoto

Shiraki

et al . Clinical significance of tumor markers in detection of recurrent hepatocellular carcinoma after radiofrequency ablation. Int J Mol Med 2010; 26: 425–433.

19.

Nishikawa

Inuzuka

Takeda

et al . Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. J Gastroenterol 2011; 46: 1418–1426.

20.

Kawamura

Ikeda

Fujiyama

et al . Potential of a no-touch pincer ablation procedure that uses a multipolar radiofrequency ablation system to prevent intrasubsegmental recurrence of small and single hepatocellular carcinomas. Hepatol Res 2017; 47: 1008–1020.

21.

Tierney

Stewart

Ghersi

et al . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.

22.

Minami

Tateishi

Shiina

et al . Comparison of improved prognosis between hepatitis B- and hepatitis C-related hepatocellular carcinoma. Hepatol Res 2015; 45: E99–E107.

23.

Tateishi

Shiina

Yoshida

et al . Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 2006; 44: 1518–1527.

24.

Tamura

Igarashi

Suda

et al . Fucosylated fraction of alpha-fetoprotein as a predictor of prognosis in patients with hepatocellular carcinoma after curative treatment. Dig Dis Sci 2010; 55: 2095–2101.

25.

Dohi

Nouso

Miyahara

et al . Potential of alpha-fetoprotein as a prognostic marker after curative radiofrequency ablation of hepatocellular carcinoma. Hepatol Res 2016; 46: 916–923.

26.

Tajiri

Baba

Kawai

et al . Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection. J Gastroenterol Hepatol 2016; 31: 1291–1299.

27.

Lee

Rhim

Kim

et al . Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma. Liver Int 2016; 36: 580–587.

28.

Cucchetti

Piscaglia

Cescon

et al . Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013; 59: 300–307.

29.

Sultanik

Ginguay

Vandame

et al . Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse(R) G600 analyzer. J Viral Hepat 2017; 24: 80–85.

30.

Kim

Hyuck

Kwon

et al . Protein induced by vitamin K antagonist-II (PIVKA-II) is a reliable prognostic factor in small hepatocellular carcinoma. World J Surg 2013; 37: 1371–1378.

31.

Baek

Lee

Jang

et al . Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepato-gastroenterology 2009; 56: 763–767.

32.

Zhang

et al . Diagnostic accuracy of des-gamma-carboxy prothrombin versus alpha-fetoprotein for hepatocellular carcinoma: A systematic review. Hepatol Res 2014; 44: E11–E25.

33.

Toyoda

Kumada

Osaki

et al . Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: A preliminary report. Cancer Sci 2012; 103: 921–925.

34.

Kurokawa

Yamazaki

Mitsuka

et al . Prediction of vascular invasion in hepatocellular carcinoma by next-generation des-r-carboxy prothrombin. Br J Cancer 2016; 114: 53–58.

35.

Zhang

Chu

Cui

et al . Des-gamma-carboxy prothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma. Cell Physiol Biochem 2014; 34: 903–915.

36.

Suzuki

Shiraha

Fujikawa

et al . Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem 2005; 280: 6409–6415.

37.

Fujikawa

Shiraha

Ueda

et al . Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J Biol Chem 2007; 282: 8741–8748.

38.

Wang

Cheng

Cui

et al . Des-gamma-carboxy prothrombin stimulates human vascular endothelial cell growth and migration. Clin Exp Metastasis 2009; 26: 469–477.

39.

Gao

Cui

Chen

et al . Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells. Life Sci 2008; 83: 815–820.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.32 MB